Melbourne, Australia – The global rise in obesity and diabetes is leading to an epidemic in fatty liver disease affecting 20-30 per cent of the world’s population. Almost a third of people with fatty liver disease go on to develop an advanced form of the disease, known as non-alcoholic steatohepatitis...
Latest News
SOUTH SAN FRANCISCO, Calif. – Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Micki Klearman, M.D. to its Board of Directors. “Micki’s addition to the board is instrumental as we continue to evaluate the...
NIJMEGEN, Netherlands — Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announced that the United States Patent and Trademark Office and the European Patent Office have granted patents covering the use of Khondrion’s lead compound sonlicromanol as an [mPGES-1 inhibiting] anti-inflammatory agent. Sonlicromanol...
For more than two years, Tobey Miller hasn’t been able to read her baby bedtime stories and kiss him good night. The only home he has ever known has been a room at Cardinal Glennon Children’s Medical Center, more than two hours away from her. A rare kidney disease —...
Osaka, Japan – Guillain–Barré syndrome (GBS), a rare immune-mediated peripheral neuropathy that can cause permanent disability and even death and be quite severe to manage. In this acute disorder, which typically triggers after a respiratory or gastrointestinal tract infection, the body’s immune system attacks its own peripheral nerves, damaging the...
ESCONDIDO — A five-year-old kindergarten student at Pioneer Elementary School is recovering from pertussis, or whooping cough, health officials said Tuesday. The child developed the bacterial disease even after receiving the recommended five-part course of vaccinations, officials said. County Public Heath Officer Wilma Wooten explained that while the whooping cough...
SEATTLE, WA — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. KVA12123, Kineta’s novel VISTA blocking...
SAN DIEGO – Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that a multiyear research grant from Luxembourg National Research Fund (FNR) and Cancer Foundation Luxembourg has been awarded to Doctor Anna Golebiewska Ph.D., co-leading...
SAN DIEGO – Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or are resistant to, current treatment regimens today announced topline data results from the newly-diagnosed adjuvant arm of its open-label, Phase 2 clinical study being conducted at the...
SAN DIEGO – Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has been activated...